Metagenomi (MGX) Stock Price, News & Analysis

Company Overview

Metagenomi, Inc. is a biotechnology company focused on developing genetic medicines using genome-editing technologies. The company uses metagenomics—the study of genetic material recovered from environmental microorganisms—to discover and characterize naturally occurring CRISPR systems and other programmable enzymes that may offer advantages over conventional gene-editing tools.

Metagenomi’s technology platform is designed to support the development of therapies for genetic diseases by enabling targeted DNA editing, including gene insertion, deletion and correction. Its research activities have included the discovery of novel nucleases and other genome-editing components, as well as the advancement of potential therapeutic programs in areas such as metabolic and liver-related disorders.

Founded in 2018, Metagenomi is based in Emeryville, California. The company’s work is primarily focused on research and development, with its products and programs intended for potential use in human medicine rather than commercial sale. Metagenomi became a publicly traded company on the Nasdaq under the symbol MGX in 2024.

Key Stats

• Today's Range: $0.68 to $0.72
• 50-Day Range: $0.71 to $1.19
• 52-Week Range: $0.60 to $2.23
• Volume: 138,559 shs
• Average Volume: 191,674 shs
• Market Capitalization: $26.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Metagenomi Stock Analysis - MarketRank™

Metagenomi scored higher than 72% of companies evaluated by MarketBeat, and ranked 192nd out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Metagenomi has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Metagenomi has a consensus price target of $6.00, representing about 749.9% upside from its current price of $0.71.

Amount of Analyst Coverage

Metagenomi has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Metagenomi are expected to grow in the coming year, from ($2.50) to ($1.76) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Metagenomi is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Metagenomi is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Metagenomi has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.91% of the float of Metagenomi has been sold short.

Short Interest Ratio / Days to Cover

Metagenomi has a short interest ratio ("days to cover") of 6.26.

Change versus previous month

Short interest in Metagenomi has recently increased by 1.60%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Metagenomi does not currently pay a dividend.

Dividend Growth

Metagenomi does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.22

News Sentiment

Metagenomi has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Metagenomi this week, compared to 1 article on an average week.

Search Interest

5 people have searched for MGX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.

MarketBeat Follows

2 people have added Metagenomi to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $23,400.00 in company stock, which represents 0.0877% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Metagenomi insiders have bought more of their company's stock than they have sold. Specifically, they have bought $23,400.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.50% of the stock of Metagenomi is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Metagenomi has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/10/2026
• Next Earnings (Estimated): 11/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MGX
• Previous Symbol: NASDAQ:MGX
• CIK: 1785279
• Web: www.metagenomi.co
• Phone: 510-871-4880
• Fax: N/A
• Employees: 113
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Metagenomi: $6.00
• High Price Target: $7.00
• Low Price Target: $5.00
• Potential Upside/Downside: +752.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.49)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$87.87 million
• Net Margins: -384.61%
• Pretax Margin: -690.60%
• Return on Equity: -63.65%
• Return on Assets: -44.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.50
• Quick Ratio: 4.50

Sales & Book Value

• Annual Sales: $25.21 million
• Price / Sales: 1.06
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.22 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 37,780,000
• Free Float: 33,055,000
• Market Cap: $26.60 million
• Optionable: N/A
• Beta: 0.82